

Eric D Whitman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1210838/publications.pdf>

Version: 2024-02-01

30
papers

3,195
citations

331642

21
h-index

501174

28
g-index

31
all docs

31
docs citations

31
times ranked

4639
citing authors

#	ARTICLE	IF	CITATIONS
1	RE: More sentinel lymph node biopsies for thin melanomas after transition to AJCC 8th edition do not increase positivity rate: A Danish population-based study of 7148 patients. <i>Journal of Surgical Oncology</i> , 2022, 125, 1343-1344.	1.7	0
2	Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial. <i>Clinical Cancer Research</i> , 2022, 28, 1157-1166.	7.0	16
3	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2656-2666.	1.6	145
4	Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3829-3838.	1.6	44
5	Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction. <i>JCO Precision Oncology</i> , 2021, 5, 1466-1479.	3.0	17
6	P865 Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies independent review committee data update. , 2020, , .		3
7	Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. <i>Immunity</i> , 2020, 53, 1095-1107.e3.	14.3	273
8	Outcomes of retreatment with anti-PD-1 monotherapy after response to first course in patients with cutaneous melanoma. <i>Future Oncology</i> , 2020, 16, 1441-1453.	2.4	7
9	Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices. <i>Future Oncology</i> , 2019, 15, 459-471.	2.4	27
10	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520.	10.7	183
11	Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIb-IVM1c melanoma. <i>Melanoma Research</i> , 2018, 28, 44-51.	1.2	31
12	Vemurafenib treatment for patients with locally advanced, unresectable stage IIIc or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. <i>Melanoma Research</i> , 2017, 27, 585-590.	1.2	21
13	Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 1309-1319.	1.5	117
14	Variations in time to receiving first surgical treatment for breast cancer as a function of racial/ethnic background: a cohort study. <i>JRSM Open</i> , 2014, 5, 204253331351586.	0.5	24
15	Role of sentinel lymphadenectomy in thin cutaneous melanomas with positive deep margins on initial biopsy. <i>Journal of Surgical Oncology</i> , 2012, 106, 363-368.	1.7	18
16	gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma. <i>New England Journal of Medicine</i> , 2011, 364, 2119-2127.	27.0	809
17	Factors Predictive of the Status of Sentinel Lymph Nodes in Melanoma Patients from a Large Multicenter Database. <i>Annals of Surgical Oncology</i> , 2011, 18, 3593-3600.	1.5	78
18	A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. <i>Investigational New Drugs</i> , 2011, 29, 161-166.	2.6	120

#	ARTICLE	IF	CITATIONS
19	A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. <i>Melanoma Research</i> , 2010, 20, 218-226.	1.2	90
20	Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor- α -Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5763-5771.	1.6	540
21	Molecular classification of melanomas and nevi using gene expression microarray signatures and formalin-fixed and paraffin-embedded tissue. <i>Modern Pathology</i> , 2009, 22, 538-546.	5.5	48
22	Pharmacokinetics of Histamine Dihydrochloride in Healthy Volunteers and Cancer Patients: Implications for Combined Immunotherapy with Interleukin-2. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 774-781.	2.0	11
23	Results From a Randomized Phase III Study Comparing Combined Treatment With Histamine Dihydrochloride Plus Interleukin-2 Versus Interleukin-2 Alone in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 125-133.	1.6	130
24	Complications associated with the use of central venous access devices. <i>Current Problems in Surgery</i> , 1996, 33, 309-378.	1.1	61
25	Comparative analysis of laparoscopic versus open splenectomy. <i>American Journal of Surgery</i> , 1996, 172, 596-601.	1.8	178
26	Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 β . <i>Annals of Surgical Oncology</i> , 1995, 2, 151-159.	1.5	21
27	Venographic surveillance of tunneled venous access devices in adult oncology patients. <i>Annals of Surgical Oncology</i> , 1995, 2, 174-178.	1.5	57
28	Vascular Access for Therapeutic Plasma Exchange. <i>Artificial Organs</i> , 1994, 18, 305-308.	1.9	5
29	Endocrine Surgical Diseases of Elderly Patients. <i>Surgical Clinics of North America</i> , 1994, 74, 127-144.	1.5	31
30	A PERSISTENT OUTBREAK OF MEASLES DESPITE APPROPRIATE PREVENTION AND CONTROL MEASURES. <i>American Journal of Epidemiology</i> , 1987, 126, 438-449.	3.4	90